Matthew Wheeler retweeted
Don't miss your chance to learn about #NIH_CFDE #data resources and a new platform for querying the Gene Expression Omnibus (GEO) with #gene sets! Tune in to this webinar on Fri 5/31 at 1PM ET. Learn more: bit.ly/3vX6iJK
0
1
1
1,165
Now online from @me_lindholm and @DavidAm79279702 and colleagues of the #MoTrPAC consortium - explore the underlying data at motrpac-data.org and analysis R packages led by @nicolergay at github.com/MoTrPAC/Motrpa…
New! Online now: The mitochondrial multi-omic response to exercise training across rat tissues dlvr.it/T6KTp8
1
1
12
1,750
If you’re looking for the #MoTrPAC @Nature paper after exploring the data at motrpac-data.org here is the pdf link: rdcu.be/dGpGX
0
1
1
468
Explore the underlying data at motrpac-data.org
This week in Nature: Exercise effects - Mapping the molecular changes induced by endurance

Browse the full issue: nature.com/nature/volumes…
1
1
14
1,697
Matthew Wheeler retweeted
Replying to @me_lindholm
@NatMetabolism @CellGenomics @NatureComms To explore this data, go to motrpac-data.org. Here you can download data, look at how exercise regulates your favorite genes/proteins/metabolites across tissues or interactively compare training-induced tissue- and sex-specific enrichments in your tissues of interest. /n
1
1
7
733
Matthew Wheeler retweeted
0
23
81
12,814
Moving day! #AcademicTwitter See you at genomic.social thanks for all the fish
0
1
0
So amazing to see this preprint out - incredible work by the entire #MoTrPAC team and especially co-leads @nicolergay @DavidAm79279702 @PierreMichelJ10! Thanks to @NIH_CommonFund for continuing support
We are thrilled to share the preprint for the Molecular Transducers of Physical Activity Consortium’s (aka MoTrPAC) first major multi-omic multi-tissue exercise study and data resource! biorxiv.org/cgi/content/sh…
0
2
12
Matthew Wheeler retweeted
All all data underlying MetaDome.app , including annotations of all human codons to @PfamDB-based evolutionary equivalent positions, are now available and ready to be plugged into your analysis pipeline.

Available here:
zenodo.org/record/6625251
0
3
9
Excited to see #mavacamten approval for patients with symptomatic obstructive hypertrophic cardiomyopathy! Spudich lab @stanford fundamental biophysics facilitating MyoKardia small molecule, trials @StanfordMed since 2015 - SAD, EXPLORER, VALOR, MAVA-LTE…more work to be done 1/4
2
9
60
Replying to @MWheelerMD
Importantly Mavacamten is first in class, with other sarcomere modulators in trials…we hope to learn more through clinical roll-out and PMA studies. Thanks to collaborators at MYOK and BMS. Thanks to Masataka Kawana and our clinical research team over the past 7 years…3/4
1
0
5
Replying to @MWheelerMD
And of course huge thanks to the many patient participants here and elsewhere who have collectively volunteered years of their time to ensure data collected (including through the pandemic) continues to be high quality. 4/4
0
0
5
Congrats to rising star @ADevareddyMD @StanfordMedRes for presenting our results analyzing progression of disease in the pre-#mavacamten era using serial CPET testing in #HCM patients @StanfordMed #ACC22 @euanashley @jwc14 @Ron_Witteles
1
6
31
Article Ideation by Artificial Intelligence vs Actual Individuals bmj.com/content/375/bm…
0
0
1
Matthew Wheeler retweeted
Replying to @NatureRevGenet
Our featured article: The genetics of human performance go.nature.com/2VIjZKt #Review by @danseungkim, @MWheelerMD & @euanashley
@StanCVFellows @StanfordDeptMed @Stanford
Free to read here: rdcu.be/cxKrt #SharedIt
0
9
34
Matthew Wheeler retweeted
Replying to @TiaMoscarello
@euanashley @MWheelerMD @vnparikh @ChloeReuterCGC @juliaplatt And TOMORROW from 12-1pm Pacific Time, we will be welcoming pioneers in clinical cardiovascular genetics, Dr. Richard Bagnall, PhD and Professor Chris Semsarian, all the way from Australia! Register here: bit.ly/32iAEHA.
@rdbagnall @CSHeartResearch
1
7
11
Matthew Wheeler retweeted
1
14
16
Intellia, with first results, delivers a 'landmark' for CRISPR gene editing biopharmadive.com/news/intellia-… via @BioPharmaDive
1
1
10
Replying to @MWheelerMD
But we will have to see if there are any longer term unintended off target (both tissue and gene) effects that this prelim report don’t address. Reminder for TTR patients out there there are efficacious treatments approved and available, though cost is a real concern
1
0
1
Replying to @MWheelerMD
Look forward to more data from the sponsors, academics and further trials in terms of in vivo genome scale edits across tissues
0
0
2